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Abstract
Background and aims—Drug-induced liver injury (DILI) is a serious adverse drug event that
is suspected to have a heritable component. We carried out a genome-wide association study of
783 individuals of European ancestry who experienced DILI due to more than 200 implicated
drugs.
Methods—DILI patients from the US-based Drug-Induced Liver Injury Network (n = 401) and
three international registries (n = 382) were genotyped with the Illumina 1Mduo BeadChip and
compared with population controls (n = 3001). Potential associations were tested in 307
independent Drug-Induced Liver Injury Network cases.
Results—After accounting for known major histocompatibility complex risk alleles for
flucloxacillin-DILI and amoxicillin/clavulanate-DILI, there were no genome-wide significant
associations, including in the major histocompatibility complex region. Stratification of DILI
cases according to clinical phenotypes (injury type, latency, age of onset) also did not show
significant associations. An analysis of hepatocellular DILI (n = 285) restricted to 193 single-
nucleotide polymorphisms previously associated with autoimmune disease showed a trend
association for rs7574865, in the vicinity of signal transducer and activator of transcription 4
(STAT4) (P = 4.5 × 10−4). This association was replicated in an independent cohort of 168
hepatocellular DILI cases (P = 0.011 and 1.5 × 10−5 for combined cohorts). No significant
associations were found with stratification by other clinical or demographic variables.
Conclusion—Although not significant at the genome-wide level, the association between
hepatocellular DILI and STAT4 is consistent with the emerging role of the immune system in
DILI. However, the lack of genome-wide association study findings supports the idea that strong
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genetic determinants of DILI may be largely drug-specific or may reflect rare genetic variations,
which were not assessed in our study.
Keywords
drug-induced liver injury; genome-wide association study; pharmacogenetics
Introduction
Idiosyncratic drug-induced liver injury (DILI) is a major cause of acute liver failure [1], but
this statistic alone considerably underestimates the public health impact of DILI. For
example, concern for DILI can limit patient access to drugs that might otherwise be
beneficial. There are currently no tests available that can definitively establish the diagnosis
of DILI or indicate which drug is responsible if a patient takes multiple medications. As a
consequence, key drugs may be unnecessarily stopped, thereby creating a health risk to the
patient. DILI is also the single, major adverse event that leads to termination of clinical drug
development programs and to regulatory actions on approved drugs [2]. Concern for a DILI
event during early clinical trials frequently leads to longer and larger clinical trials requested
by the FDA, thus delaying patient access to important new medications and increasing the
costs of bringing new drugs into the market. Improved understanding of underlying DILI
mechanisms could lead to clinical tests that might be used to identify patients susceptible to
DILI from a given drug, to confirm the diagnosis of DILI, and to help to identify the
offending agent in a patient taking multiple drugs. This understanding should also lead to
improved preclinical methodology to detect DILI potential in new drug candidates.
A strategy to identify the mechanisms underlying DILI has been genetic analysis of patients
who have actually experienced DILI. The studies to date support the concept that DILI
susceptibility results in part from genetic variation in at least four major classes of genes:
drug metabolism including toxification and detoxification enzymes, drug and bile acid
transporters, cellular stress response genes, and innate and adaptive immune response genes
including the major histocompatibility complex (MHC) region genes [3,4].
We hypothesized that some DILI susceptibility factors are shared across multiple drugs for
several reasons. Individual drug-metabolizing enzymes and drug transporters are often able
to transport or metabolize many different drug substrates. Thus, individual DILI risk factors
at the level of enzymes and transporters could incur a risk for multiple drugs. Similarly,
cellular responses to stress are finite and risk factors in these pathways would likely not be
drug-specific. Furthermore, previous genetic associations support the concept that specific
genetic susceptibility variants may be shared by different drugs [3,4]. Finally, common risk
factors for DILI are supported by the observation that in a cohort of Spanish DILI patients,
nine had experienced more than one discrete episode of DILI due to different drugs [5],
suggesting that some individuals may be particularly susceptible to DILI from multiple
agents.
We carried out a genome-wide association study (GWAS) of DILI in 783 individuals of
European ancestry who experienced DILI due to a large number of implicated drugs (> 200).
Possible associations were then evaluated in a smaller replication cohort (n = 307). This
report represents the largest investigation of DILI genetics to date.
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Cases (n = 783) were recruited from four separate studies [Drug-Induced Liver Injury
Network (DILIN) [6], DILIGEN [7], EUDRAGENE [8], and the Spanish DILI Registry
[9]]. A total of 565 cases were recruited from the DILIN network between August 2004 and
April 2009 from eight DILIN clinical sites in the USA; 401 cases of European ancestry were
included in the current study. The contribution of cases of European ancestry from the other
networks was as follows: DILIGEN, 242 cases; EUDRAGENE, 89 cases; and Spanish DILI
Registry, 51 cases. All participants provided written informed consent and each study was
approved by the appropriate institutional review boards. Details of recruitment and the
inclusion and exclusion criteria for these networks have been published previously [10]. For
all cases in the DILIN, causality assessment was by expert consensus as described
previously [6], whereas the Roussel-Uclaf causality assessment method (RUCAM) was used
in the other three registries [11]. Notably, the cases studied here include 296 samples from
DILI patients with injury attributed to flucloxacillin or amoxicillin/clavulanate that overlap
almost completely with the samples used in previous reports [7,10]. These were included
here to identify the common variants contributing to DILI susceptibility across different
drugs, and should not be taken as replicating previous published genetic associations. The
replication cohort consisted of 307 cases from the DILIN network. Genotyped controls (n =
655) from the Population Reference Sample (POPRES, n = 655) [12] and the 1958 British
Birth Cohort (http://www.b58cgene.sgul.ac.uk) (n = 2346) were used for comparison.
Replication studies utilized genotype data from the National Blood Service cohort (n =
2249). Genotype data for the 1958 British Birth Cohort and the National Blood Service
cohort were provided by the Wellcome Trust Case–Control Consortium (http://
www.wtccc.org.uk).
Secondary phenotypes
Cases were categorized as hepatocellular versus cholestatic versus mixed using the R-value
[11]. Other secondary phenotypes included demographic or clinical strata (sex, age greater
than or less than the median, time to onset greater than or less than the median, presence of
eosinophilia, fever, or rash). Because experienced hepatologists enrolled each patient only
after concluding that the patients probably had DILI, and because causality assessment
protocols were not uniform across the different cohorts, our primary analyses were carried
out on all cases where genotyping data were available. When potential associations were
evident, post-hoc analyses were carried out by dichotomizing the sample into those with a
causality score of at least probable (DILIN score of ‘probable’, ‘very likely’, or ‘definite’;
RUCAM ≥ 6) versus those with causality less than probable (see Supplementary Tables S1
and S2, http://links.lww.com/FPC/A505).
Genotyping
DNA was prepared as described previously [10]. Genome-wide genotyping of the European
DILI cases and POPRES controls was carried out by Expression Analysis Inc. (Durham,
North Carolina, USA) and of the USA cases by the Center for Human Genome Variation,
Duke University. Genotype data for the 1958 British Birth Cohort controls were provided by
the Wellcome Trust Case–Control Consortium 2. All patients were genotyped using the
Illumina Human1M or 1MDuo BeadChip (Illumina Inc., San Diego, California, USA), each
containing greater than 1 000 000 markers. A total of 800 769 markers, 783 cases (401
DILIN, 242 DILIGEN, 89 EUDRAGENE, and 51 Spanish DILI Registry), and 3001
controls passed quality control carried out as described previously [13].
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Population structure of the combined case and control sample was estimated by principal
components analysis using a modification of EIGENSTRAT [14] as described previously
[13]. Tests for association between the single-nucleotide polymorphism (SNP) genotype and
DILI were carried out using logistic regression in PLINK [15] using the top 14 principal
components emerging from the EIGENSTRAT analyses as covariates in the model. Where
applicable, the top-associated SNPs in the MHC region for flucloxacillin-DILI (rs2395029)
and amoxicillin/clavulanate-DILI (rs2523822, rs3135388) that were present in the quality
control filtered dataset were also included as covariates to determine whether any risk for
all-drug DILI may be explained by other variants after correcting for these known DILI risk
alleles. Association test results were annotated and visualized using the WGAviewer
software [16]. We also carried out hypothesis-guided exploratory analysis of genes involved
in drug absorption, distribution, metabolism, and excretion (ADME) [17], or non-HLA
genes known to be generally involved in autoimmune diseases [18], as described previously
[10].
Replication genotyping was carried out using TaqMan SNP Genotyping Assays (Life
Technologies, Carlsbad, California, USA). Replication testing was carried out using the χ2
or Fisher’s exact test of allele frequency differences between 307 European-ancestry DILI
cases enrolled in the DILIN network not included in the GWAS and 2587 samples of
European descent from the National Blood Service. Combined P-values for the discovery
and replication sets were calculated using Stouffer’s weighted Z method. Power estimates
were performed using the PGA software [19].
Results
Characteristics of the study population
The DILI case samples included a discovery cohort of 783 patients of primarily European
ancestry, all of which were genotyped on the Illumina 1M or 1Mduo BeadChip; a replication
cohort consisting of 307 US patients who were self-identified White, non-Hispanic, was
available from the DILIN for follow-up of variants of interest emerging from the GWAS.
The demographic and clinical characteristics of both cohorts are shown in Table 1. The
representation of implicated drugs (Table 2) was comparable between cohorts, with the
exception of flucloxacillin, which was absent from the US-based (DILIN) replication cohort,
and amoxicillin/clavulanate.
Genome-wide association study results: all drug-induced liver injury cases
Principal components analysis showed that the 783 DILI cases and 3001 controls were well
matched ancestrally (Supplementary Fig. S1, http://links.lww.com/FPC/A505). When all
case patients were included in the analysis, we observed a large number of SNPs in the
MHC region on chromosome 6p with genome-wide significance (Fig. 1a and d). The MHC
region has been shown previously to contain high-impact risk alleles for DILI due to
flucloxacillin and amoxicillin/clavulanate, and in fact, these MHC associations for
flucloxacillin and amoxicillin/clavulanate have been reported previously using DNA
samples from individuals overlapping significantly with the participants in the current study
[7,10]. These cases were included here to improve power to detect novel genetic
associations (anywhere in the genome) with DILI risk across all drugs. Given that these
samples represent a large fraction of the case sample in the GWAS (Table 2) and may thus
obscure other MHC associations with DILI due to other drugs, we also carried out a GWAS
utilizing only DILI cases not explained by these two drugs. In the analysis of 487 DILI cases
not attributed to flucloxacillin or amoxicillin/clavulanate, the observed P-value distribution
genome-wide was not different from that expected under the null hypothesis, and no single
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SNP in the MHC region or elsewhere exceeded the typical threshold for genome-wide
statistical significance (P < 10−8), (Fig. 1b and e). Similarly, when all drugs were
considered, but the association tests were carried out conditional on the known MHC DILI
risk SNPs for flucloxacillin and amoxicillin/clavulanate [7,10], no genome-wide significant
associations were detected (Fig. 1c and f, Table 3).
As the MHC region has been implicated previously in DILI risk through GWAS, we
determined whether the MHC region may be enriched for SNPs associated with DILI risk
after the exclusion of the flucloxacillin and amoxicillin/clavulanate cases. Among the 487
non-flucloxacillin, non-amoxicillin/clavulanate-related DILI cases, we observed a lower P-
value distribution among SNPs in the extended MHC region (chr6: 26 000 000–35 500 000)
compared with all other autosomal SNPs (Supplementary Fig. S4A, S4B, http://
links.lww.com/FPC/A505). To account for linkage disequilibrium prevalent in the MHC
region, we randomly permuted the phenotype–genotype relationship among all individuals
and repeated the association tests in the MHC region 1000 times. Among 1000
permutations, the observed median P-value in the observed (unpermuted) data (0.381) was
in the lower 1.5 percentile of the median P-values in the MHC region (empirical P = 0.015,
Supplementary Fig. S4C, http://links.lww.com/FPC/A505).
Drug metabolism and transporter single-nucleotide polymorphism analysis
Because drug-metabolizing enzymes and transporters have been assumed to play critical
roles in mechanisms underlying DILI, we tested whether any SNPs in the vicinity of 130
genes involved in ADME [17] showed a greater degree of association with DILI risk than
expected by chance. We found that several SNPs in the region of ABCC2 (encoding the
multidrug resistance-associated protein MRP2) were the most associated SNPs in the
ADME category (Table 3). The P-value corresponding to the highest associated SNP
(rs3740065; P = 2.6 × 10−5) approached the specified threshold for significance after
multiple test correction (P < 10−5). In addition, post-hoc analysis showed that the association
with this SNP became stronger as the analysis was restricted to individuals with time to
onset less than 30 days and causality scores of ‘probable’ or greater (RUCAM ICC ≥ 6 or
DILIN causality of ‘probable’, ‘very likely’, or ‘definite’) (P = 2.5 × 10−6) (Supplementary
Table S4, http://links.lww.com/FPC/A505). However, in a replication cohort of 304
independently genotyped DILI cases and 2249 controls from the National Blood Service
cohort, there was no evidence of an association between rs3740065 and DILI risk (P = 0.49)
(Table 4). Of note, no significant association with SNPs in the vicinity of the bile salt
excretory protein gene (ABCB11) or manganese superoxide dismutase (SOD2) genes was
found, although these have been implicated previously in DILI mechanisms [3,4].
Autoimmune single-nucleotide polymorphism analysis
We next tested whether any of the 193 SNPs associated previously with autoimmune
diseases might have a stronger association with DILI risk than expected by chance. This
analysis (conditioned on genotypes at the known MHC risk alleles for DILI due to
flucloxacillin and amoxicillin/clavulanate) showed rs2476601 in the protein tyrosine
phosphatase nonreceptor type 22 (PTPN22) gene to be the top-associated autoimmune SNP
(Table 3). This association appeared to be driven solely by the cases classified as having a
cholestatic injury type (see the section below).
Genome-wide association study results: clinical strata and drug-specific or class-specific
analyses
The results of the stratified analyses are shown in Supplementary Figs S5–S38 (http://
links.lww.com/FPC/A505) and Supplementary Tables S5–S38 (http://links.lww.com/FPC/
A505). Among the clinically defined strata, the most notable results were from the
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autoimmune-associated SNP sets, which showed experiment-wide significance (i.e. after
correction for multiple testing of 193 autoimmune-associated SNPs) for an association
between rs2476601, a nonsynonymous coding SNP in the PTPN22 gene, and cholestatic
injury (P = 5.4 × 10−7), and rs7574865 in the vicinity of signal transducer and activator of
transcription 4 (STAT4), which showed an almost experiment-wide significant (P = 4.5
10−4) association with hepatocellular injury (Table 4). Although the association between
rs2476601 and cholestatic injury was almost genome-wide significant and would have been
declared significant within the autoimmune-restricted SNP analysis, this association was not
replicated in the independent cohort of 105 cholestatic DILI cases (P = 0.26, with the trend
in the opposite direction of that observed in the discovery cohort). The lack of replication
could not be attributed to the lower representation of amoxicillin/clavulanate and the
absence of flucloxacillin cases in the replication cohort as the other cholestatic DILI cases [n
= 77, odds ratio (OR) 2.32 (1.45–3.70), P = 4.3 × 10−4] contributed to an equivalent degree
to the initial apparent association as did the flucloxacillin and amoxicillin/clavulanate cases
[n = 110, OR 2.14 (1.46–3.18), P = 1.2 × 10−4]. The association between rs7574865 located
near the STAT4 gene and hepatocellular injury was found to replicate in an independent set
of 168 cases, although the estimated effect size and strength of association was reduced
compared with the discovery cohort (Table 4).
No other associations approaching the specified levels of significance were observed,
including examinations by time to onset, age of onset, presence of extrahepatic signs, or
severity of injury.
Among the drug-specific or class-specific tests, the most notable results in the GWAS
analyses were found for diclofenac (rs17036170, upstream of the PPARG gene, P = 1.07 ×
10−8) and NSAIDs (rs9376256, an intergenic SNP in the region of IL20RA and IL22RA2, P
= 6.7 × 10−8). In the ADME-restricted analysis of fluoroquinolone DILI cases, rs17862876
in the region of the UDP-glycosyltransferase-encoding UGT1A gene showed almost
experiment-wide significance (3.4 × 10−5). In the autoimmune-restricted analysis of DILI
due to statins, the rs7574865 polymorphism near STAT4 reached experiment-wide
significance (P = 4.9 × 10−5). However, for all drug and drug class-specific associations,
attempts to replicate the observed findings in independent cohorts were unsuccessful (or
ambiguous in the case of diclofenac/PPARG) (Table 4). The lack of replication was not
explained by differences in the allele frequency between discovery and replication control
cohorts (P ≥ 0.1 for the difference in frequency between control datasets for all SNPs, except
rs17862876, which showed a slightly lower risk allele frequency in the replication controls
(P = 0.018) and thus would be biased toward association in the same direction as in the
discovery set). Neither could it be explained by platform differences in genotyping: among
401 patients of European ancestry from the DILIN cohort genotyped using both the Illumina
1Mduo BeadChip and single-site TaqMan assays, there was perfect concordance in
genotype calls across platforms. No associations approaching significance were observed in
other drug or drug class cohorts.
Power calculations
As no genome-wide significant associations were found in our analysis, we then calculated
what magnitude of effect [in terms of relative risk (RR)] from truly associated common
SNPs would likely have been missed in our analyses. As shown in Fig. 2a, the current
sample size (793) provides sufficient power (> 80%) to detect SNPs conferring RR more
than 2, and almost complete power to detect the effects of SNPs carrying RR greater than
2.5, even for a relatively low-frequency SNP [minor allele frequency (MAF) = 0.05,
typically among the lowest frequency SNPs included in GWAS] (Fig. 2a). For the majority
of the common SNP frequency spectrum (i.e. MAF > 10%), the current study was estimated
to have almost complete power to detect the effects of SNPs carrying RR greater than 1.5
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(Fig. 2b). However, analyses of less than 200 cases, which were typical in our analyses of
clinical strata, would have fairly low power to detect RR less than 3, and the drug-specific or
class-specific analyses utilizing case samples totaling 30 or fewer would generally be
powered only to detect common variants with fairly large effects (RR > 5) (Table 5).
Further, we estimated the influence of the use of unselected population controls relative to
drug-exposed controls on statistical power to detect a genetic association. As suggested
previously [20], for rare diagnoses such as DILI, the low rate of expected misclassification
of control samples has a negligible effect on power (Supplementary Table S39, http://
links.lww.com/FPC/A505).
Discussion
If only a limited number of mechanisms were responsible for idiosyncratic DILI events,
preclinical tests could reliably screen and limit drug candidates for DILI liability, and in
principle, a ‘DILI chip’ could be used to screen patient populations to identify susceptible
individuals and to potentially aid in the diagnosis of DILI. We therefore hoped to find strong
and unambiguous associations between common variants and all-cause DILI at the genome-
wide significance threshold. However, once the previously described MHC associations
with flucloxacillin and amoxicillin/clavulanate-DILI were excluded, no significant genome-
wide associations were found in our large cohort of DILI cases attributed to diverse drugs.
Because the proposed mechanisms of DILI involve drug metabolism and disposition and
immune response, we next restricted our analysis to SNPs in the vicinity of ADME genes
and those associated previously with susceptibility to autoimmune diseases. None of the
ADME SNP associations suggested in the test cohort were confirmed in the validation
cohort.
For the autoimmune analysis only, the association between hepatocellular DILI and an SNP
near the STAT4 gene was also observed in the validation cohort; however, the effect
appeared to be attenuated in the validation sample. STAT4 is involved in inflammation
through the regulation of several cytokines and has been implicated in T-cell maturation
[21]. To our knowledge, this is the first reported association of an innate immune gene with
DILI across a large number of implicated drugs, and supports a potential role of innate
immunity in DILI. However, this association did not meet the typical rigorous threshold for
significance in a genome-wide study. The reduced effect size observed in the validation
cohort suggests the possibility of a ‘winner’s curse’ effect, but is also consistent with a
chance association: given the seven SNPs carried forward for validation testing, it is not
unlikely that one of them would continue to show an association in the validation cohort
simply due to chance. We therefore cannot conclude that this is a true association, but we
believe further study of the possible relationship between STAT4 variation and
hepatocellular DILI is warranted.
Although our sample sizes for each implicated drug were generally small, we found some
interesting trends toward associations with specific drugs. For example, an SNP upstream of
the PPARG gene was associated with diclofenac DILI at almost the genome-wide
significance level and with an OR of 30 (Table 4). Diclofenac has been shown previously to
interact with the PPARγ receptor at pharmacologic concentrations of the drug [22], and
PPARγ activation has been shown to influence inflammation, specifically by diclofenac
[23,24]. Although this strong association was not replicated in our second cohort, the trend
was in the same direction, the replication cohort was small, and the association in the
combined cohorts remained almost genome-wide significant. Given the biological
plausibility of this association, additional studies are warranted. For statin cases, an
association with a STAT4 SNP reached specified significance for the autoimmune-restricted
analysis but also did not replicate in our second smaller cohort. Given the large population
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receiving statin medications and the current controversy about the DILI risk that statins pose
[25], this observation also requires additional studies.
It seems unlikely that the lack of replication of tentative associations indicates differences in
the characteristics of the discovery and replication samples. The larger proportion of
amoxicillin/clavulanate and flucloxacillin-DILI cases in the discovery cohort did not appear
to account for the failure to replicate, and other characteristics such as severity of injury,
causality assessment, or patient characteristics appeared to be comparable between cohorts.
Genotype calls between the GWAS chip and the targeted TaqMan assays were also perfectly
concordant for all samples examined. The most likely reason for failure to replicate
associations of interest (Table 4) therefore may be that these were simply false associations.
This is consistent with the fact none of the variants carried forward to replication achieved
genome-wide significance in the discovery cohort, and most of the variants selected on the
basis of the ADME-restricted or autoimmune-restricted analysis were only approaching or
barely surpassing a more lenient threshold for significance.
Recently reported GWAS have identified common alleles in the MHC region as risk factors
for DILI [7,10,26,27,28]. If an adaptive immune attack on the liver is the final common
event that causes significant liver injury, it is possible that only patients carrying certain
MHC alleles are at risk of DILI from a specific drug, that is, ‘upstream’ events (e.g.
hepatocyte accumulation of critical reactive metabolites or bile acids) may be necessary but
not sufficient to produce DILI. We therefore carried out an exploratory analysis of the
association signal in the MHC region compared with autosomal regions outside of the MHC
after excluding DILI cases due to flucloxacillin or amoxicillin/clavulanate. Although the P-
value distribution was lower in the MHC region compared with elsewhere (Supplementary
Fig. S4, http://links.lww.com/FPC/A505), after permutation testing, the enrichment of the
association signal in the MHC region only approached significance (empirical P = 0.015).
The observed trend toward enrichment could be due to the extremely high degree of linkage
disequilibrium among SNPs in the MHC region and/or an artifact of uncorrected population
structure, as low-frequency subpopulation-specific variants in the MHC may not be
accounted for by principal components analysis based largely on common variants outside
of the MHC. Our analysis therefore does not support the concept of common MHC variation
as a general risk factor for DILI, but does not exclude drug-specific or drug subset-specific
effects.
On the basis of the power calculations carried out (Fig. 2), we estimate that common
variants conferring the risk of a moderate effect size (i.e. RR ≥ 1.5) to all-cause DILI should
have been discovered in our study. It is of note that in our initial GWAS analysis of all DILI
cases, the MHC signals driven solely by the flucloxacillin and amoxicillin/clavulanate cases
were appreciable at the genome-wide significance level (Fig. 1), although these cases
account for only 38% of the cohort. As a further example of the ability to detect strong
associations despite gross misclassification of phenotype, an analysis that included DILI
cases due to flucloxacillin and all other drugs except amoxicillin/clavulanate identified the
rs2395209 association (due to flucloxacillin) at the genome-wide significance level, despite
the fact that flucloxacillin made up only 13.4% of the total cases (Fig. 3). Individuals
carrying the HLA-B*5701 allele have about an 80-fold increased risk of developing DILI
when treated with flucloxacillin [7]. Hence, if any combination of individuals comprising a
similarly small fraction of our cohort had a common risk factor with comparable effect, we
would have detected it in our GWAS analysis. The fact that no other risk variants were
detected in the genome-wide analyses is therefore an important negative finding for
identifying common SNPs with a very strong effect on DILI risk.
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Our negative GWAS findings may suggest that future efforts should focus on collecting and
analyzing DILI cases due to single drugs. However, collecting sufficient cases will be a
challenge; although the HLA-B*5701 association with flucloxacillin-DILI (OR~80) would
have been detected by GWAS with as few as 12 cases, our data suggest that such strong
associations with common variants are unusual. With amoxicillin/clavulanate-DILI, more
than 50 cases would be required to demonstrate an HLA association by GWAS (OR~3) [10].
Test and replication cohorts of this size may simply not be feasible for most drugs
implicated in the existing registries. If there in fact exist common genetic variants that
underlie susceptibility to DILI, it may still be feasible to identify them with GWAS if a
sufficient number of DILI cases due to diverse drugs could be ‘clustered’ by a common
mechanism or surrogates for mechanism. For example, it may be possible to use
chemoinformatic approaches or biological effects (e.g. induction of STAT4 in cell culture or
transport by MRP2) as surrogates for mechanisms to create subgroupings for GWAS.
Our use of population controls deserves comment. As DILI is such a rare event (occurring
on average in fewer than one in 10 000 patients), the expected rate of misclassification of
control individuals using unselected population controls is very low and should not
appreciably impact statistical power to detect a genetic association ([20], Supplementary
Table S39, http://links.lww.com/FPC/A505). However, this study design does not allow us
to directly test for the effects of environmental risk factors for DILI, such as age, sex, or
diagnosis/indication for the precipitant drug(s), among other factors. In particular,
polypharmacy (i.e. patients taking a large number of concomitant drugs, even if only one is
truly hepatotoxic) has been suggested as a risk factor for DILI [29], perhaps due to
competition for, metabolism, or active transport out of hepatocytes or enzyme induction.
Only common genetic variants (predominantly variants with allele frequencies exceeding
5%) were genotyped in our patients. For an event frequency of less than one in 10 000, as is
typical for DILI, it is not possible for common variants individually to have highly specific
associations with susceptibility. Analytical approaches that could detect the synergistic
effects of multiple SNPs are fraught with statistical (multiple comparison) and
computational hurdles and such investigations would probably need to be directed by solid
data on biological plausibility. It should also be acknowledged that effects not captured by
GWAS or genome sequencing are likely to also contribute to DILI risk, including epigenetic
or environmental effects as described above. Nonetheless, the availability of the DILI gene
banks and the rapidly evolving genomic technology available currently make genetic
investigation of DILI a high-priority area of research. Weak but detectable genetic
contributions to risk should show important mechanistic pathways whose epigenetic or
environmental influences could then be studied specifically.
Conclusion
GWAS of the largest DILI cohort assembled to date was unable to identify any major
genetic risk factors associated with DILI. Restricted analyses showed a replicated
association between all-cause hepatocellular injury and STAT4, which should be further
confirmed. Although the lack of significant GWAS findings does not rule out a highly
polygenic model of many variants with a small effect on DILI risk, our data support the idea
that very strong associations may be largely drug-specific or reflect rare genetic variations
that may only be shown through ongoing advancements in next-generation sequencing. It
also seems likely that the maximal yield from genetic interrogation will require parallel
experimental approaches to define subgroups of drugs likely to have common mechanisms
of DILI or to identify specific biological pathways implicated in DILI.
Urban et al. Page 10














Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank the DILIGEN, EUDRAGENE, Spanish DILI, iSAEC, and DILIN collaborators for their help
with case recruitment.
The authors acknowledge use of genotype data from the British 1958 Birth Cohort DNA collection and UK
National Blood Service control cohorts. This study makes use of data generated by the Wellcome Trust Case–
Control Consortium. A full list of the investigators who contributed to the generation of the data is available from
http://www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113 and
085475.
The DILIN network is structured as a U01 cooperative agreement with funds provided by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) under grants: 2U01-DK065176-06 (Duke), 2U01-
DK065201-06 (UNC), 2U01-DK065184-06 (Michigan), 2U01-DK065211-06 (Indiana), 5U01DK065193-04
(UConn), 5U01-DK065238-08 (UCSF/CPMC). Additional funding is provided by CTSA grants: UL1 RR025761
(Indiana), UL1 RR025747 (UNC), and UL1 UL1 RR024986 (UMich).
The DILIGEN sample collection was partly funded by the UK Department of Health (Pharmacogenetics Initiative
ref PHGX10A), UK NIHR funding to the Nottingham Digestive Diseases Centre, and the iSAEC. The
EUDRAGENE collaboration has received support from the EC 5th Framework program (QLRI-CT-2002-02757)
and the iSAEC. M.M. has received funding from a UK NIHR postdoctoral award and is an investigator for the FP7
EU-ADR (ICT-215847) and ARITMO (HEALTH-241679) projects on drug safety. The Spanish DILI Registry is
partly funded by the Spanish Medicine Agency and has received support from the iSAEC. CIBERehd is funded by
Instituto de Salud Carlos III.
The genome-wide genotyping of DILIN cases was funded by the NIDDK under grant 2U01-DK065176-06.
Genome-wide genotyping of the DILIGEN, Dundee, EUDRAGENE, Spanish DILI Registry and GSK POPRES
controls was funded by iSAEC, with support from Abbott, Daiichi-Sankyo, GSK, J & J, Novartis, Pfizer, Roche,
Sanofi-Aventis, Takeda, the Wellcome Trust and Wyeth.
References
1. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a
prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern
Med. 2002; 137:947–954. [PubMed: 12484709]
2. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn
more about acute drug-induced liver injury. Hepatology. 2008; 48:1680–1689. [PubMed:
18853438]
3. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic
studies. Pharmacogenomics. 2009; 10:1467–1487. [PubMed: 19761370]
4. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010; 11:607–
611. [PubMed: 20415545]
5. Lucena MI, Kaplowitz N, Hallal H, Castiella A, Garcia-Bengoechea M, Otazua P, et al. Recurrent
drug-induced liver injury (DILI) with different drugs in the Spanish Registry. The dilemma of the
relationship to autoimmune hepatitis. J Hepatol. 2011
6. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced
Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;
32:55–68. [PubMed: 19132805]
7. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Péer I, Floratos A, et al. HLA-B*5701 genotype is a
major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009; 41:816–819.
[PubMed: 19483685]
8. Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA
collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics. 2006;
7:633–638. [PubMed: 16753010]
Urban et al. Page 11













9. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced
liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.
Gastroenterology. 2005; 129:512–521. [PubMed: 16083708]
10. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to
amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.
Gastroenterology. 2011
11. Danan G, Benichou C. Causality assessment of adverse reactions to drugs – I. a novel method
based on the conclusions of international consensus meetings: application to drug-induced liver
injuries. J Clin Epidemiol. 1993; 46:1323–1330. [PubMed: 8229110]
12. Nelson MR, Bryc K, King KS, Indap A, Boyko AR, Novembre J, et al. The Population Reference
Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am
J Hum Genet. 2008; 83:347–358. [PubMed: 18760391]
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B
predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461:399–401. [PubMed:
19684573]
14. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components
analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38:904–
909. [PubMed: 16862161]
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for
whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;
81:559–575. [PubMed: 17701901]
16. Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ, et al. WGAViewer: software for genomic
annotation of whole genome association studies. Genome Res. 2008; 18:640–643. [PubMed:
18256235]
17. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD, et al. A single-nucleotide
polymorphism tagging set for human drug metabolism and transport. Nat Genet. 2005; 37:84–89.
[PubMed: 15608640]
18. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential
etiologic and functional implications of genome-wide association loci for human diseases and
traits. Proc Natl Acad Sci USA. 2009; 106:9362–9367. [PubMed: 19474294]
19. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association
analyses. BMC Genet. 2008; 9:36. [PubMed: 18477402]
20. Edwards BJ, Haynes C, Levenstien MA, Finch SJ, Gordon D. Power and sample size calculations
in the presence of phenotype errors for case/control genetic association studies. BMC Genet. 2005;
6:18. [PubMed: 15819990]
21. Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, mechanisms, and
implications for autoimmunity. Curr Allergy Asthma Rep. 2008; 8:398–403. [PubMed: 18682104]
22. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome
proliferator-activated receptor-gamma signaling. Mol Pharmacol. 2002; 61:7–12. [PubMed:
11752200]
23. Kaur J, Sanyal SN. Modulation of inflammatory changes in early stages of colon cancer through
activation of PPARgamma by diclofenac. Eur J Cancer Prev. 2010; 19:319–327. [PubMed:
20485182]
24. Zieleniak A, Wojcik M, Wozniak LA. Structure and physiological functions of the human
peroxisome proliferator-activated receptor gamma. Arch Immunol Ther Exp (Warsz). 2008;
56:331–345. [PubMed: 18836859]
25. Bader T. Liver tests are irrelevant when prescribing statins. Lancet. 2010; 376:1882–1883.
[PubMed: 21109303]
26. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study
identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010; 42:711–
714. [PubMed: 20639878]
27. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1*02:01 Is a major
risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin
Oncol. 2011; 29:667–673. [PubMed: 21245432]
Urban et al. Page 12













28. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-
wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of
immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;
8:186–195. [PubMed: 17505501]
29. Suzuki A, Yuen N, Walsh J, Papay J, Hunt CM, Diehl AM. Co-medications that modulate liver
injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin
Gastroenterol Hepatol. 2009; 7:882–888. [PubMed: 19362607]
Urban et al. Page 13














Manhattan and Quantile–quantile plots of association study results including (a, d) or
excluding (b, e) drug-induced liver injury (DILI) cases due to amoxicillin/clavulanate or
flucloxacillin, for which strong genetic risk variants in the MHC region have been identified
previously [7]. The genome-wide association study was also carried out including all cases,
but conditioned on the known major histocompatibility complex single-nucleotide
polymorphisms associated with flucloxacillin-induced or amoxicillin/clavulanate-induced
DILI (c, f). The Manhattan plot shows the location along the genome on the x-axis and the –
log10 P-value along the x-axis. A P-value less than 10−8 was considered significant. The
quantile–quantile plot shows in rank order the observed P-values versus those expected
under the null hypothesis, showing adequate correction for population structure (genomic
inflation factor, λ = 1.02) and significant deviation from the null for the top-associated
SNPs only in the analysis including amoxicillin/clavulanate and flucloxacillin cases.
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Power estimates for the identification of drug-induced liver injury risk variants given
available sample sizes. (a) Power versus sample size over a range of relative risk, assuming
a minor allele frequency of 0.05, sample size: n = 783 cases versus n = 3000 controls,
population prevalence of 1 : 10 000, and significance threshold P < 10−8. (b) Detectable
relative risk (RR) versus risk allele frequency over a range of power (1 – β), assuming r2 = 1
between the marker and the causal risk allele, and sample sizes and significance threshold as
above.
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Manhattan (a) and Quantile–quantile (b) plots of genome-wide association study results for
the analysis of all drug-induced liver injury (DILI) cases including flucloxacillin, but
excluding amoxicillin/clavulanate-induced DILI cases. Despite the fact that flucloxacillin-
DILI cases make up only 13.4% of the total case sample (75/560), there remains clear
evidence of an HLA-B*5701 (rs2395029) association with DILI risk in the combined
sample, suggesting that misclassification or heterogeneity of cases is unlikely to obscure the
true DILI risk variants of a very large effect (the HLA-B*5701 allele confers an 80-fold
increased risk of DILI from flucloxacillin [7]).
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Table 1
Clinical characteristics of the study population in the initial discovery sample used for genome-wide
association study (n=783) and in the replication cohort (n=307)
N (%) or median (range)
Variables Discovery sample Replication sample
Sex
 Male 329 (42.0) 136 (44.3)
 Female 454 (58.0) 171 (55.7)
Age of onset (years) 57.5 (1.8–98) 54.2 (5.8–88)
Time to onset (days) 24 (0–7045) 39 (0–11463)
Injury type
 Cholestatic 187 (23.9) 90 (29.3)
 Mixed 164 (20.9) 64 (20.8)
 Hepatocellular 256 (32.7) 139 (45.3)
 Unknown/unclassified 176 (22.5) 14 (4.6)
Severity
 Mild 105 (13.4) 50 (16.3)
 Moderate 80 (10.2) 62 (20.2)
 Moderate (hospitalized) 124 (15.8) 48 (15.6)
 Severe 47 (6.0) 32 (10.4)
 Fatal 20 (2.6) 16 (5.2)
 Unknown/unclassified 407 (52.0) 99 (32.2)
Causality score
 ‘Unlikely’ or ‘possible’ 83 (10.6) 35 (11.4)
 ‘Probable’, ‘very likely’, ‘definite’ 622 (79.4) 173 (56.4)
 Unknown/unclassified 78 (10.0) 99 (32.2)
Immunoallergic features
 Eosinophilia 46 (5.9) NA
 Fever 161 (20.6) NA
 Rash 125 (16.0) NA
 Any of above 256 (32.7) NA
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Table 2
The most common drugs implicated in drug-induced liver injury cases (drugs with n ≥ 5) in both the discovery






Amoxicillin/clavulanate 208 (26.6) 42 (13.7)
Flucloxacillin 75 (9.6) 0 (0.0)
Diclofenac 30 (3.8) 4 (1.3)
Nitrofurantoin 24 (3.1) 15 (4.9)
Isoniazid 17 (2.2) 7 (2.3)
Sulfamethoxazole/trimethoprim 14 (1.8) 14 (4.6)
Valproic acid 13 (1.7) 2 (0.6)
Nimesulide 12 (1.5) 0 (0.0)
Minocycline 10 (1.3) 17 (5.5)
Celecoxib 8 (1.0) 1 (0.3)
Flucloxacillin and amoxicillin/
 clavulanate
8 (1.0) 0 (0.0)
Ciprofloxacin 7 (0.9) 9 (2.9)
Phenytoin 7 (0.9) 1 (0.3)
Azathioprine 6 (0.8) 5 (1.6)
Duloxetine 6 (0.8) 0 (0.0)
Telithromycin 6 (0.8) 0 (0.0)
Atorvastatin 5 (0.6) 3 (1.0)
Simvastatin 5 (0.6) 4 (1.3)
All other drugs and combinations 322 (41.1) 183 (59.6)
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Table 3
The top-associated variants in all drug-induced liver injury cases
a
 for all single-nucleotide polymorphisms and
selected subsets of single-nucleotide polymorphisms associated with absorption, distribution, metabolism, and
excretion and autoimmune genes
SNP Sets SNP P-value Chromosome:coordinate Function Nearest gene
Genome-wide rs35709459 1.99E – 07 X:91516677 Intronic PCDH11X
rs35925943 1.38E – 06 X:91516339 Intronic PCDH11X
rs11767067 1.64E – 06 7:93022840 Intergenic CALCR
rs1187997 2.18E – 06 1:58455538 Intronic DAB1
rs656437 4.24E – 06 11:95770378 Intronic MAML2
ADME subset rs3740065 0.0001 10:101605693 Intronic ABCC2
rs2756113 0.0008 10:101569371 Intronic ABCC2
rs2804397 0.0011 10:101559415 Intronic ABCC2
rs8187710 0.0013 10:101611294 Missense (C1515Y) ABCC2
rs11816708 0.0013 10:101615015 Downstream ABCC2
Autoimmune subset rs2476601 2.26E – 05 1:114377568 Missense (R620W) PTPN22
rs6679677 4.18E – 05 1:114303808 Upstream RSBN1
rs7202877 0.0002 16:75247245 Intergenic CTRB1
rs1464510 0.003 3:188112554 Intronic LPP
rs12928822 0.0033 16:11403893 Upstream MIR548H2
ADME, absorption, distribution, metabolism, and excretion; SNP, single-nucleotide polymorphism.
a
Analysis conditioned on rs2395029, rs2523822, and rs3135388, known to be highly associated with drug-induced liver injury due to flucloxacillin
or amoxicillin/clavulanate.
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Table 5
Detectable effect size for common variants (minor allele frequency = 10%) as a function of the number of case
samples versus 3000 controls






Available sample sizes for stratified analyses include those on the order of 100–200 for injury type and other clinical strata, which should be able to
detect moderate effects of common variants (genotype relative risk on the order of 2–3). Some drug-specific analyses were carried out using
sample sizes in the range of 10–30 individuals, which have low power to detect moderate effects but are well powered to detect very large effects
(genotype relative risks of 5–10 or greater). These estimates assume a minor allele frequency of 0.10, a control sample of 3000, a population
prevalence of drug-induced liver injury 1 : 10 000, and a significance threshold P<10−8.
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